Nasdaq:US$18.03 (+0.20) | HKEX:HK$28.20 (-0.25) | AIM:£2.85 (+0.05)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors